Skip to main content
Public offering brings in $12.2M for Interpace Diagnostics

Interpace Diagnostics has obtained $12.2 million in net proceeds from its public offering of 9.9 million shares of common stock, common warrants to buy 12.5 million shares and prefunded warrants to buy 2.6 million shares. The net proceeds will be used as working capital, as well as for general corporate functions, payment of legacy contract sales organization obligations and trade payables.

Full Story: